3-ethyl-2-methyl-thiazolidine | 143487-30-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 3-ethyl-2-methyl-thiazolidine
• 英文别名: 3-Ethyl-2-methyl-1,3-thiazolidine
• CAS: 143487-30-3
• 化学式: C₆H₁₃NS
• 分子量: 131.242
• InChiKey: ZNOREPRETSSXDV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  28.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-ethyl-2-methyl-thiazolidine 、 alkaline earth salt of/the/ methylsulfuric acid 生成 1,3-bis-(3-ethyl-4,5-dihydro-thiazol-2-yl)-trimethinium; perchlorate
  参考文献：
  名称：

  Coenen,M.; Riester,O., Justus Liebigs Annalen der Chemie, 1960, vol. 633, p. 110 - 118

  摘要：

  DOI：

文献信息

• [EN] PHOTOPOLYMER COMPRISING A NEW CLASS OF PHOTO INITIATOR<br/>[FR] PHOTOPOLYMÈRE COMPRENANT UNE NOUVELLE CLASSE DE PHOTO-INITIATEUR
  申请人：COVESTRO DEUTSCHLAND AG

  公开号：WO2016096639A1

  公开（公告）日：2016-06-23

  The present invention relates to photopolymer comprising a photopolymerizable component and a photo initiator system. Further aspects of the present invention are a holographic media which comprises such a photopolymer, a display which comprises such a holographic media and the use of such a holographic media to make chip cards, security documents, bank notes and / or holographic optical elements especially for displays.

  本发明涉及包括光聚合物可聚合组分和光引发剂系统的光聚合物。本发明的进一步方面包括包括这种光聚合物的全息介质、包括这种全息介质的显示器以及利用这种全息介质制作芯片卡、安全文件、银行票据和/或用于显示器的全息光学元件。
• Ether Compounds for Treatment of Complement Mediated Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20150239920A1

  公开（公告）日：2015-08-27

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is an ether (R 32 ) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

  提供了有关制备抑制补体因子D的化合物、使用方法和制备过程，所述化合物包括具有式I的化合物，或其药用可接受的盐或组合物，其中A组上的R12或R13是醚（R32）。本文描述的抑制剂靶向因子D并在替代性补体途径的早期和关键点上抑制或调节补体级联，并减少因子D调节经典和凝集素补体途径的能力。本文描述的因子D抑制剂能够减少过度激活的补体，这与某些自身免疫、炎症和神经退行性疾病、缺血再灌注损伤和癌症有关。
• [EN] CONDENSED PENTACYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF FLAVIVIRIDAE INFECTIONS<br/>[FR] DÉRIVÉS PENTACYCLIQUES CONDENSÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT D'INFECTIONS DE FLAVIVIRIDAE
  申请人：GENELABS TECH INC

  公开号：WO2009086139A1

  公开（公告）日：2009-07-09

  Provided are compounds of Formula (I) or a pharmaceutically acceptable salt or solvate thereof. The compounds and compositions are useful for treating viral infections caused by the Flaviviridae family of viruses.

  提供的是式（I）的化合物或其药学上可接受的盐或溶剂。这些化合物和组合物可用于治疗由黄病毒科病毒引起的病毒感染。
• Compounds for Treatment of Complement Mediated Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20150239838A1

  公开（公告）日：2015-08-27

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

  提供了包括公式I或其药学上可接受的盐或组合物的补体因子D抑制剂的化合物、使用方法和制备方法。本文所描述的抑制剂靶向因子D并在替代补体途径的早期和关键点上抑制或调节补体级联反应，并减少因子D调节经典和凝集素补体途径的能力。本文所述的因子D抑制剂能够减少补体过度激活，该过度激活已与某些自身免疫性、炎症性和神经退行性疾病以及缺血再灌注损伤和癌症有关。
• Amide Compounds for Treatment of Complement Mediated Disorders
  申请人：ACHILLION PHARMACEUTICALS, INC.

  公开号：US20150239893A1

  公开（公告）日：2015-08-27

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R 12 or R 13 on the A group is an amide substituent (R 32 ) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

  提供了包含式I的补体因子D抑制剂的化合物、使用方法和制备方法，或其药学上可接受的盐或组合物，其中A组上的R12或R13是酰胺取代基（R32）。本文所描述的抑制剂靶向因子D并在替代补体途径的早期和基本点上抑制或调节补体级联反应，并减少因子D调节经典和凝集素补体途径的能力。本文所述的因子D抑制剂能够减少过度激活补体，这与某些自身免疫、炎症和神经退行性疾病、缺血再灌注损伤和癌症有关。